Fatty liver is an independent risk factor for gallbladder polyps

Table 2 Comparison of baseline characteristics between the subjects with and without gallbladder polyps

Characteristics	GBP group (n = 1405)	Control group (n = 2810)	P value
Age (yr)	46.84 ± 11.72	46.84 ± 11.72	> 0.999
Gender (male, %)	897 (63.8%)	1794 (63.8%)	> 0.999
BMI (kg/m2)	23.93 ± 3.04	23.94 ± 3.34	0.866
Waist circumference (cm)	84.30 ± 9.04	84.36 ± 9.48	0.844
Visceral fat area (cm2)	92.38 ± 32.51	94.52 ± 38.50	0.059
ASM (kg)	20.88 ± 5.22	20.76 ± 5.00	0.452
Sarcopenia (%)	87 (6.2%)	215 (7.7%)	0.087
Hypertension (%)	643 (45.8%)	1273 (45.3%)	0.793
Diabetes (%)	116 (8.3%)	266 (9.5%)	0.211
Metabolic syndrome (%)	307 (21.9%)	626 (22.3%)	0.783
Fatty liver (%)	643 (45.8%)	1173 (41.7%)	0.013
Biochemistry
AST (IU/L)	26.02 ± 17.18	27.80 ± 15.39	0.001
ALT (IU/L)	26.50 ± 22.88	29.02 ± 22.00	0.001
Alkaline phosphatase (IU/L)	66.18 ± 18.63	67.22 ± 19.48	0.099
Gamma-glutamyltransferase (IU/L)	31.00 ± 66.11	33.99 ± 46.29	0.089
hs-CRP (mg/dL)	0.16 ± 0.65	0.14 ± 0.38	0.249
Total cholesterol (mg/dL)	195.29 ± 36.24	197.40 ± 35.75	0.071
Triglyceride (mg/dL)	113.40 ± 73.21	117.28 ± 79.25	0.125
HDL cholesterol (mg/dL)	54.98 ± 13.52	55.09 ± 13.76	0.812
CEA (ng/mL)	1.63 ± 1.05	1.61 ± 1.00	0.574
CA19-9 (IU/mL)	10.59 ± 9.17	10.80 ± 11.32	0.548
HBsAg (%)	53 (3.9%)	85 (3.1%)	0.200
HCV Ab (%)	5 (0.4%)	12 (0.4%)	> 0.999

Data are presented as mean± SD or number (%). GBP: Gallbladder polyp; BMI: Body mass index; ASM: Appendicular skeletal muscle mass; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; hs-CRP: High-sensitivity C-reactive protein; HDL: High-density lipoprotein; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; HBsAg: Hepatitis B virus surface antigen; HCV Ab: Hepatitis C virus antibody.